Cascade Pharmaceuticals

Executive Summary

Cascade Pharmaceuticals is a clinical-stage biotechnology company based in Nanjing, China, specializing in the discovery and development of targeted small molecule therapies for oncology. Leveraging structure-based drug design, the company aims to inhibit key cancer pathways with high selectivity and potency. Its lead programs are currently advancing through early clinical trials, targeting solid tumors with significant unmet medical needs. Founded in 2005 and privately held with 50-200 employees, Cascade has established a pipeline focused on novel kinase inhibitors and other precision oncology agents. The company's strategy aligns with the growing demand for effective and well-tolerated oral therapies in oncology, particularly in the Asian market where it operates.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead asset (CS001) in advanced solid tumors35% success
• Q1 2027IND filing for next-generation kinase inhibitor (CS002)70% success
• Q2 2027Potential partnership or licensing deal for Asian ex-China rights50% success